_edited.png)
Unlock Hard-to-reach Cohorts in Healthcare and Life Sciences With
Real-World Evidence
Dispersed patient groups and rural health disparities pose challenges for the Great Plains and Rocky Mountains region that only valuable data can transform into Real World Evidence (RWE) you can leverage.
Substantiating Value to Payers.
Securing Reimbursement.
In a competitive, cost-driven market, securing formulary placement demands real-world evidence beyond clinical trials. Waller Hall RWE delivers tailored analyses, comparative effectiveness, adherence, and resource utilization, to prove a therapy’s economic value. Their data strengthens HTA negotiations and validates value for regional payers and Medicare Advantage plans.
Start Leading With Evidence
Traditional clinical trials and health initiatives often overlook real-world patient usage patterns, particularly those with co-morbidities, different socioeconomic backgrounds, or living in rural areas. This oversight undermines scientific validity and market potential. By directly tackling this operational challenge, we provide clear evidence of disease natural history and true effectiveness in diverse, real-world patient populations.
​
-
Demonstrate Value to the FDA: Evidence packages are built on verifiable data provenance and robust analytical methods, designed specifically to meet the high standards of regulatory acceptance and fit-for-purpose designation.
​
-
Accelerate Label Expansion: Clients utilize quantified real-world outcomes to support new indications and effective lifecycle management, unlocking patient groups previously inaccessible through conventional means
Scientific Rigor in Heterogeneity
The foundational challenge of RWD, incomplete datasets, inconsistent coding, and unreliable provenance, is critically amplified across the fragmented Great Plains and Rocky Mountain provider landscape. Waller Hall Research’s proprietary methodology and specialized regional competency ensure that even the most complex, disparate RWD is transformed into credible, valid evidence.
​
Waller Hall Research acts as a strategic partner in transforming the complexity of the Real World into a definitive competitive differentiator, providing the analytical certainty required for accelerated commercial success.
Featured RWE Service Offerings
-
Regulatory-Grade Evidence Generation and Submission Support: We provide the foundational work—including transparent data provenance, meticulous quality assessment, and robust analytical methods, to ensure your RWE is "Regulatory-Grade" and prepared for high-stakes examinations by the FDA. We support approvals for new indications and help fulfill post-approval study requirements.
​
-
Market Access and Value Quantification Analysis: Our services focus on generating the evidence needed to strengthen payer negotiations. We perform comparative effectiveness, adherence, and resource-utilization analyses to quantify clinical benefits in routine care settings, directly supporting Health Technology Assessment (HTA) submissions and favorable reimbursement decisions.
​
-
Post-Market Safety Surveillance and Pharmacovigilance: Beyond clinical trials, we conduct continuous safety surveillance at a population scale, utilizing large, longitudinal datasets to detect rare adverse events and reveal risk factors in specific patient subgroups, such as the elderly or those with co-morbidities.
​
-
Geographically Distributed Cohort Assembly and Rural Outcomes: We specialize in overcoming the geographic isolation of the Great Plains and Rocky Mountains by assembling dispersed research cohorts for rare diseases or targeted therapeutics. This generates powerful insights into patient populations, such as those with co-morbidities, specific age groups, or rural, high-disparity socio-demographic groups, often excluded from traditional RCTs